27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Vanda Pharmaceuticals Inc (NASDAQ:VNDA) announced the results from its Phase 3 study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant effectively prevents vomiting associated with motion sickness.
- The Phase 3 study was conducted in real-world conditions on boats in the coastal waters of the U.S.
- Also Read: Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug.
- In the Motion Syros study, 365 participants embarked on boat trips under varied sea conditions and received tradipitant 170 mg, tradipitant 85 mg, or placebo.
- Study participants had a prior history of motion sickness and were distributed across thirty-four boat trips between November 2021-April 2023.
- 170 mg and 85 mg tradipitant doses were superior to placebo in preventing vomiting, with only 18.3% and 19.5% of participants experiencing vomiting on tradipitant 170 mg and 85 mg, respectively, compared to 44.3% of participants on placebo.
- The FDA has not approved a new medication for motion sickness in over forty years since scopolamine, a transdermal patch placed behind the ear, was approved in 1979.
- Price Action: VNDA shares are down 1.39% at $6.03 on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!